Akebia commences dosing in AKB-9778 Phase 1 research for diabetic macular edema and retinopathy Akebia Therapeutics, Inc. AKB-9778 is designed to stabilize vessels in the rear of the eye, stopping vascular leak and abnormal blood vessel growth connected with diabetic attention disease. Based on years of analysis and data from preclinical studies, we believe that AKB-9778 has the potential to become a major advance for individuals with DR and DME erectile dysfunction treatment . This mix of actions is ideal to handle the two principal causes of vision loss in patients with DME and DR and is certainly supported by data in multiple preclinical models of retinopathy. The Stage 1 study is designed to evaluate the protection, tolerability and pharmacokinetics of single ascending dosages of AKB-9778 in healthy volunteers.
But it's also possible that using both drugs together impairs teens' driving-and judgment-to a larger degree. Terry-McElrath said it's vital that you make kids-and the public, in general-aware of the risks of simultaneous drug make use of. Driver's education needs to chat more about the dangers, in believable ways-not using inaccurate scare strategies, she said. More broadly, she added, press communications about unsafe driving should go beyond alcohol. We frequently hear the message 'Don't drink and drive,' Terry-McElrath mentioned.